Interferon‑induced protein 16 expression in colorectal cancer and its correlation with proliferation and immune signature markers

Zou,Yunlian; Zhang,Jinping; Zhang,Lichen; Yan,Xinmin

doi:10.3892/ol.2021.12948

Interferon‑induced protein 16 expression in colorectal cancer and its correlation with proliferation and immune signature markers

Authors:
- Yunlian Zou
- Jinping Zhang
- Lichen Zhang
- Xinmin Yan
View Affiliations

Affiliations: Faculty of Environmental Science and Engineering, Kunming University of Science and Technology, Kunming, Yunnan 650500, P.R. China, Institute of Medical Sciences, Yunnan Blood Disease Clinical Medical Center, The First People's Hospital of Yunnan Province, Affiliated Hospital of Kunming University of Science and Technology, Kunming, Yunnan 650032, P.R. China, Medical Faculty, Kunming University of Science and Technology, Kunming, Yunnan 650500, P.R. China
Published online on: July 28, 2021 https://doi.org/10.3892/ol.2021.12948
Article Number: 687
Copyright: © Zou et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Interferon‑induced protein 16 (IFI16) is important for innate immune recognition of foreign/damaged DNA. Abnormal IFI16 expression is closely related to the occurrence of multiple malignant tumours, but its expression pattern in colorectal cancer (CRC) remains unclear. The present study aimed to investigated IFI16 expression and association with cell proliferation in CRC tissues and adjacent normal tissues. A multiplex immunofluorescence panel of antibodies against IFI16, Ki‑67 and phosphorylated (p)‑ERK1/2 was applied to assess a tissue microarray (TMA). The TMA included 77 CRC samples and 74 normal adjacent tissue samples which were collected from The First People's Hospital of Yunnan Province (Kunming, China) (3 paracancerous tissues were lost because of repeated cutting). Immunohistochemistry was used to detect CD8+ tumour‑infiltrating lymphocyte (TIL) abundance and programmed death‑ligand 1 (PD‑L1) expression in cancer tissues. The present study demonstrated that IFI16 localized to the nucleus of CRC cells. Although IFI16 was weakly expressed in normal mucosal epithelial cells, absent to strong expression was detectable in different patients with CRC. Typically, IFI16 was not co‑localized with Ki‑67 within CRC cells. The multiplex immunofluorescence data demonstrated that the proportion of IFI16‑/Ki‑67+ cells from CRC tissues was 57.13%; however, that of IFI16+/Ki‑67+ cells was 1.50%. The IFI16‑/Ki‑67+ phenotype was significantly positively associated with the tumor‑node‑metastasis stage and was marginally significantly correlated with lymph node metastasis. p‑ERK1/2 protein was primarily localized to the cytoplasm and cell membrane of CRC cells and sometimes to the nucleus. Although, IFI16 demonstrated a strong correlation with p‑ERK1/2, IFI16 did not co‑localize with p‑ERK1/2 and the proportion of IFI16 and p‑ERK1/2 double‑negative CRC cells was 84.95%. IFI16 expression displayed no significant association with CD8+ TILs or PD‑L1. However, a strong positive correlation between CD8+ TILs and PD‑L1 was observed. High CD8+ TIL infiltration in CRC tissue was associated with lower lymph node metastasis and tumor‑node‑metastasis stage. In summary, the results of the present study provided a novel insight for the role of IFI16 in CRC occurrence via the regulation of cancer cell proliferation.

View Figures

View References

1	Dekker E, Tanis PJ, Vleugels J, Kasi PM and Wallace MB: Colorectal cancer. Lancet. 394:1467–1480. 2019. View Article : Google Scholar : PubMed/NCBI
2	Siegel RL, Miller KD, Goding Sauer A, Fedewa SA, Butterly LF, Anderson JC, Cercek A, Smith RA and Jemal A: Colorectal cancer statistics, 2020. CA Cancer J Clin. 70:145–164. 2020. View Article : Google Scholar : PubMed/NCBI
3	Dawson MJ and Trapani JA: IFI 16 gene encodes a nuclear protein whose expression is induced by interferons in human myeloid leukaemia cell lines. J Cell Biochem. 57:39–51. 1995. View Article : Google Scholar : PubMed/NCBI
4	Wei W, Clarke CJ, Somers GR, Cresswell KS, Loveland KA, Trapani JA and Johnstone RW: Expression of IFI16 in epithelial cells and lymphoid tissues. Histochem Cell Biol. 119:45–54. 2003. View Article : Google Scholar : PubMed/NCBI
5	Stehlik C: The PYRIN domain in signal transduction. Curr Protein Pept Sci. 8:293–310. 2007. View Article : Google Scholar : PubMed/NCBI
6	Choubey D and Panchanathan R: IFI16, an amplifier of DNA-damage response: Role in cellular senescence and aging-associated inflammatory diseases. Ageing Res Rev. 28:27–36. 2016. View Article : Google Scholar : PubMed/NCBI
7	Lin H and Cao X: Nuclear innate sensors for nucleic acids in immunity and inflammation. Immunol Rev. 297:162–173. 2020. View Article : Google Scholar : PubMed/NCBI
8	Pancanathan R, Liu H, Leung YK, Ho SM and Choubey D: Bisphenol A (BPA) stimulates the interferon signaling and activates the inflammasome activity in meloid cells. Mol Cell Endocrinol. 415:45–55. 2015. View Article : Google Scholar : PubMed/NCBI
9	Cui J, Chen Y, Wang HY and Wang RF: Mechanisms and pathways of innate immune activation and regulation in health and cancer. Hum Vaccin Immunother. 10:3270–3285. 2014. View Article : Google Scholar : PubMed/NCBI
10	Ouchi M and Ouchi T: Role of IFI16 in DNA damage and checkpoint. Front Biosci. 13:236–239. 2008. View Article : Google Scholar : PubMed/NCBI
11	Duan X, Ponomareva L, Veeranki S and Choubey D: IFI16 induction by glucose restriction in human fibroblasts contributes to autophagy through activation of the ATM/AMPK/p53 pathway. PLoS One. 6:e195322011. View Article : Google Scholar : PubMed/NCBI
12	Zhang Y, Howell RD, Alfonso DT, Yu J, Kong L, Wittig JC and Liu CJ: IFI16 inhibits tumorigenicity and cell proliferation of bone and cartilage tumor cells. Front Biosci. 12:4855–4863. 2007. View Article : Google Scholar : PubMed/NCBI
13	Raffaella R, Gioia D, De Andrea M, Cappello P, Giovarelli M, Marconi P, Manservigi R, Gariglio M and Landolfo S: The interferon-inducible IFI16 gene inhibits tube morphogenesis and proliferation of primary, but not HPV16 E6/E7 immortalized human endothelial cells. Exp Cell Res. 293:331–345. 2004. View Article : Google Scholar : PubMed/NCBI
14	Fujiuchi N, Aglipay JA, Ohtsuka T, Maehara N, Sahin F, Su GH, Lee SW and Ouchi T: Requirement of IFI16 for the maximal activation of p53 induced by ionizing radiation. J Biol Chem. 279:20339–20344. 2004. View Article : Google Scholar : PubMed/NCBI
15	Alimirah F, Chen J, Davis FJ and Choubey D: IFI16 in human prostate cancer. Mol Cancer Res. 5:251–259. 2007. View Article : Google Scholar : PubMed/NCBI
16	Cai H, Yan L, Liu N, Xu M and Cai H: IFI16 promotes cervical cancer progression by upregulating PD-L1 in immunomicroenvironment through STING-TBK1-NF-κB pathway. Biomed Pharmacother. 123:1097902020. View Article : Google Scholar : PubMed/NCBI
17	Kim MK, Mason JM, Li CM, Berkofsky-Fessler W, Jiang L, Choubey D, Grundy PE, Tycko B and Licht JD: A pathologic link between Wilms tumor suppressor gene, WT1, and IFI16. Neoplasia. 10:69–78. 2008. View Article : Google Scholar : PubMed/NCBI
18	Yu F, Hao X, Zhao H, Ge C, Yao M, Yang S and Li J: Delta-like 1 contributes to cell growth by increasing the interferon-inducible protein 16 expression in hepatocellular carcinoma. Liver Int. 30:703–714. 2010. View Article : Google Scholar : PubMed/NCBI
19	Shi XL, Yang J, Mao N, Wu JH, Ren LF, Yang Y, Yin XL, Wei L, Li MY and Wang BN: Nutlin-3-induced redistribution of chromatin-bound IFI16 in human hepatocellular carcinoma cells in vitro is associated with p53 activation. Acta Pharmacol Sin. 36:252–258. 2015. View Article : Google Scholar : PubMed/NCBI
20	Shi X, Liu J, Liu Q and Li M: IFI16 mis-localization can be a contributing factor to hepatocellular carcinoma progression. Med Hypotheses. 82:398–400. 2014. View Article : Google Scholar : PubMed/NCBI
21	Tang H, Guo Q, Zhang C, Zhu J, Yang H, Zou YL, Yan Y, Hong D, Shou T and Yan XM: Identification of an intermediate signature that marks the initial phases of the colorectal adenoma-carcinoma transition. Int J Mol Med. 26:631–641. 2010.PubMed/NCBI
22	Yang CA, Huang HY, Chang YS, Lin CL, Lai IL and Chang JG: DNA-Sensing and nuclease gene expressions as markers for colorectal cancer progression. Oncology. 92:115–124. 2017. View Article : Google Scholar : PubMed/NCBI
23	Turkington CJR, Varadan AC, Grenier SF and Grasis JA: The viral Janus: Viruses as aetiological agents and treatment options in colorectal cancer. Front Cell Infect Microbiol. 10:6015732020. View Article : Google Scholar : PubMed/NCBI
24	Torlakovic EE, Nielsen S, Francis G, Garratt J, Gilks B, Goldsmith JD, Hornick JL, Hyjek E, Ibrahim M, Miller K, et al: Standardization of positive controls in diagnostic immunohistochemistry: Recommendations from the international Ad Hoc Expert Committee. Appl Immunohistochem Mol Morphol. 23:1–18. 2015. View Article : Google Scholar : PubMed/NCBI
25	Skaland I, Nordhus M, Gudlaugsson E, Klos J, Kjellevold KH, Janssen EA and Baak JP: Evaluation of 5 different labeled polymer immunohistochemical detection systems. Appl Immunohistochem Mol Morphol. 18:90–96. 2010. View Article : Google Scholar : PubMed/NCBI
26	Muto T, Bussey HJ and Morson BC: The evolution of cancer of the colon and rectum. Cancer. 36:2251–2270. 1975. View Article : Google Scholar : PubMed/NCBI
27	Greene FL: Current TNM staging of colorectal cancer. Lancet Oncol. 8:572–573. 2007. View Article : Google Scholar : PubMed/NCBI
28	Li LT, Jiang G, Chen Q and Zheng JN: Ki67 is a promising molecular target in the diagnosis of cancer (review). Mol Med Rep. 11:1566–1572. 2015. View Article : Google Scholar : PubMed/NCBI
29	Piccaluga PP, Agostinelli C, Righi S, Ciccone M, Re MC, Musumeci G, Diani E, Signoretto C, Bon L, Piccin O, et al: IFI16 reduced expression is correlated with unfavorable outcome in chronic lymphocytic leukemia. APMIS. 125:511–522. 2017. View Article : Google Scholar : PubMed/NCBI
30	Man SM, Karki R and Kanneganti T: DNA-sensing inflammasomes: Regulation of bacterial host defense and the gut microbiota. Pathog Dis. 74:ftw282016. View Article : Google Scholar : PubMed/NCBI
31	Veeranki S and Choubey D: Systemic lupus erythematosus and increased risk to develop B cell malignancies: Role of the p200-family proteins. Immunol Lett. 133:1–5. 2010. View Article : Google Scholar : PubMed/NCBI
32	Salama R, Sadaie M, Hoare M and Narita M: Cellular senescence and its effector programs. Genes Dev. 28:99–144. 2011. View Article : Google Scholar : PubMed/NCBI
33	Sharpless NE and Sherr CJ: Forging a signature of in vivo senescence. Nat Rev Cancer. 15:397–408. 2015. View Article : Google Scholar : PubMed/NCBI
34	Guo Y, Ayers JL, Carter KT, Wang T, Maden SK, Edmond D, Newcomb PP, Li C, Ulrich C, Yu M and Grady WM: Senescence-associated tissue microenvironment promotes colon cancer formation through the secretory factor GDF15. Aging Cell. 18:e130132019. View Article : Google Scholar : PubMed/NCBI
35	Demaria M, Q'Leary MN, Chang J, Shao L, Liu S, Alimirah F, Koening K, Le C, Mitin N, Deal AM, et al: Cellular senescence promotes adverse effects of chemotherapy and cancer relapse. Dancer Dissov. 7:165–176. 2017.PubMed/NCBI
36	Lai E, Liscia N, Donisi C, Mariani S, Tolu S, Pretta A, Persano M, Pinna G, Balconi F, Pireddu A, et al: Molecular-Biology-Driven treatment for metastatic colorectal cancer. Cancers (Basel). 12:12142020. View Article : Google Scholar : PubMed/NCBI
37	Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, et al: PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 372:2509–2520. 2015. View Article : Google Scholar : PubMed/NCBI
38	Lizardo DY, Kuang C, Hao S, Yu J, Huang Y and Zhang L: Immunotherapy efficacy on mismatch repair-deficient colorectal cancer: From bench to bedside. Biochim Biophys Acta Rev Cancer. 1874:1884472020. View Article : Google Scholar : PubMed/NCBI
39	Evrard C, Tachon G, Randrian V, Karayan-Tapon L and Tougeron D: Microsatellite instability: Diagnosis, heterogeneity, discordance, and clinical impact in colorectal cancer. Cancers (Basel). 11:15672019. View Article : Google Scholar : PubMed/NCBI
40	Keshet Y and Seger R: The MAP kinase signaling cascades: A system of hundreds of components regulates a diverse array of physiological functions. Mothods Mol Biol. 661:3–38. 2010.PubMed/NCBI
41	Sun Y, Liu WZ, Liu T, Feng X, Yang N and Zhou HF: Signaling pathway of MAPK/ERK in cell proliferation, differentiation, migration, senescence and apoptosis. J Recept Signal Transduct Res. 35:600–604. 2015. View Article : Google Scholar : PubMed/NCBI
42	Ye Q, Cai W, Zheng Y, Evers BM and She QB: ERK and AKT signaling cooperate to translationally regulate survivin expression for metastatic progression of colorectal cancer. Oncogene. 33:1828–1839. 2014. View Article : Google Scholar : PubMed/NCBI
43	Ding B and Lengyel P: p204 protein is a novel modulator of ras activity. J Biol Chem. 283:5831–5848. 2008. View Article : Google Scholar : PubMed/NCBI
44	Luan Y, Lengyel P and Liu CJ: p204, a p200 family protein, as a multifunctional regulator of cell proliferation and differentiation. Cytokine Growth Factor Rev. 19:357–369. 2008. View Article : Google Scholar : PubMed/NCBI
45	Kim EJ, Park JI and Nelkin BD: IFI16 is an essential mediator of growth inhibition, but not differentiation, induced by the leukemia inhibitory factor/JAK/STAT pathway in medullary thyroid carcinoma cells. J Biol Chem. 280:4913–4920. 2005. View Article : Google Scholar : PubMed/NCBI
46	Lengyel P and Liu CJ: The p200 family protein p204 as a modulator of cell proliferation and differentiation: A brief survey. Cell Mol Life Sci. 67:335–340. 2010. View Article : Google Scholar : PubMed/NCBI
47	Kolc W: Coordinating ERK/MAPK signalling through scaffolds and inhibitors. Nat Rev Mol Cell Biol. 6:827–837. 2005. View Article : Google Scholar : PubMed/NCBI
48	Brunet A, Roux D, Lenormand P, Dowd S, Keyse S and Pouysségur J: Nuclear translocation of p42/p44 mitogen-activated protein kinase is required for growth factor-induced gene expression and cell cycle entry. EMBO J. 18:664–674. 1999. View Article : Google Scholar : PubMed/NCBI
49	Su N, Peng L, Xia B, Zhao Y, Xu A, Wang J, Wang X and Jiang B: Lyn is involved in CD24-induced ERK1/2 activation in colorectal cancer. Mol Cancer. 11:432012. View Article : Google Scholar : PubMed/NCBI
50	Whitehurst AW, Robinson FL, Moore MS and Cobb M: The death effector domain protein PEA-15 prevents nuclear entry of ERK2 by inhibiting required interactions. J Biol Chem. 279:12840–12847. 2004. View Article : Google Scholar : PubMed/NCBI
51	Torii S, Kusakabe M, Yamamoto T, Maekawa M and Nishida E: Sef is a spatial regulator forr Ras/MAP kinase signaling. Dev Cell. 7:33–44. 2004. View Article : Google Scholar : PubMed/NCBI
52	Gil-Jaramillo N, Rocha AP, Raiol T, Motta FN, Favali C, Brigido MM, Bastos IMD and Santana JM: Trypanosoma cruzi The First Contact of human Dendritic cells with reveals response to virus as an unexplored central pathway. Front Immunol. 12:6380202021. View Article : Google Scholar : PubMed/NCBI
53	Lu N and Malemud CJ: Extracellular signal-regulated Kinase: A regulator of cell growth, inflammation, chondrocyte and bone cell receptor-mediated gene expression. Int J Mol Sci. 20:37922019. View Article : Google Scholar : PubMed/NCBI
54	Kis-Toth K, Szanto A, Thai TH and Tsokos GC: Cytosolic DNA-activated human dendritic cells are potent activators of the adaptive immune response. J Immunol. 187:1222–1234. 2011. View Article : Google Scholar : PubMed/NCBI
55	Qi Z, Yan F, Chen D, Xing W, Li Q, Zeng W, Bi B and Xie J: Identification of prognostic biomarkers and correlations with immune infiltrates among Cgas-STING in hepatocellular carcinoma. Biosci Rep. 40:BSR202026032020. View Article : Google Scholar : PubMed/NCBI
56	Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-pages C, Tosolini M, Camus M, Berger A, Wind P, et al: Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 313:1960–1964. 2006. View Article : Google Scholar : PubMed/NCBI
57	Mlecnik B, Tosolini M, Kirilovsky A, Berger A, Bindea G, Meatchi T, Bruneval P, Trajanoski Z, Fridman WH, Pagès F and Galon J: Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol. 29:610–618. 2011. View Article : Google Scholar : PubMed/NCBI
58	Payandeh Z, Khalili S, Somi M, Mard-Soltani M, Baghbanzadeh A, Hajiasgharzadeh K, Samadi N and Baradaran B: PD-1/PD-L1-dependent immune response in colorectal cancer. J Cell Physiol. 235:5461–5475. 2020. View Article : Google Scholar : PubMed/NCBI
59	Peng QH, Wang CH, Chen HM, Zhang RX, Pan ZZ, Lu ZH, Wang GY, Yue X, Huang W and Liu RY: CMTM6 and PD-L1 coexpression is associated with an active immune microenvironment and a favorable prognosis in colorectal cancer. J Immunother Cancer. 9:e0016382021. View Article : Google Scholar : PubMed/NCBI
60	Akiyoshi T, Gotoh O, Tanaka N, Kiyotani K, Yamamoto N, Ueno M, Fukunaga Y and Mori S: T-cell complexity and density are associated with sensitivity to neoadjuvant chemoradiotherapy in patients with rectal cancer. Cancer Immunol Immunother. 70:509–518. 2021. View Article : Google Scholar : PubMed/NCBI
61	Kikuchi T, Mimura K, Okayama H, Nakayama Y, Saito K, Yamada L, Endo E, Sakamoto W, Fujita S, Endo H, et al: A subset of patients with MSS/MSI-low-colorectal cancer showed increased CD8(+) TILs together with up-regulated IFN-γ. Oncol Lett. 18:5977–5985. 2019.PubMed/NCBI